Ocular aspects of myasthenia gravis

被引:73
|
作者
Barton, JJS
Fouladvand, M
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Human Vis & Eye Movement Lab, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Opthalmol,Human Vis & Eye Movement Lab, Boston, MA 02215 USA
[3] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA
关键词
ocular myasthenia; autoimmune disorder; diplopia; ptosis;
D O I
10.1055/s-2000-6829
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Ocular myasthenia gravis is a not uncommon autoimmune disorder causing diplopia, ptosis, and weakness of lid closure. The predilection of myasthenia for the ocular muscles may be related to differences between limb and extraocular muscles in either physiological function or antigenicity. Clinically ocular myasthenia can mimic any form of pupil-sparing ocular motility disorder. Dynamic abnormalities of myasthenic eye movements may reflect the primary hallmarks of the disease, which are fatigability and variability in strength, or secondary adaptive effects by the central nervous system, Tests to confirm the diagnosis include edrophonium challenge, repetitive nerve stimulation, single-fiber electromyography (EMG) of the frontalis, and assays for antibody directed against the acetylcholine receptor: all are less sensitive for ocular myasthenia than for generalized myasthenia. There is a higher incidence of other autoimmune conditions in myasthenia, notably thymoma and thyroid dysfunction. The differential diagnosis includes other diseases of the neuromuscular junction, such as Lambert-Eaton syndrome and botulism. Treatment consists of symptomatic use of acetylcholinesterase inhibitors and immunosuppression with steroids or azathioprine. Between 50 and 70% of patients with ocular myasthenia will eventually develop generalized disease: there is some retrospective data that steroids or azathioprine may reduce this by about 75%. The role of thymectomy in ocular myasthenia remains unclear.
引用
收藏
页码:7 / 20
页数:14
相关论文
共 50 条
  • [31] Ocular myasthenia gravis: A review
    Nair, Akshay Gopinathan
    Patil-Chhablani, Preeti
    Venkatramani, Devendra V.
    Gandhi, Rashmin Anilkumar
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2014, 62 (10) : 985 - 991
  • [32] Atypical ocular myasthenia gravis
    Krijnen, J
    Polman, L
    TRANSACTIONS OF THE IX INTERNATIONAL ORTHOPTIC CONGRESS, 1999, : 161 - 164
  • [33] Pediatric Ocular Myasthenia Gravis
    Fisher, Kristen
    Shah, Veeral
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2019, 21 (10)
  • [34] Childhood ocular myasthenia gravis
    Kim, JH
    Hwang, JM
    Hwang, YS
    Kim, KJ
    Chae, J
    OPHTHALMOLOGY, 2003, 110 (07) : 1458 - 1462
  • [35] Treatment of Ocular Myasthenia Gravis
    Haines, Scott R.
    Thurtell, Matthew J.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2012, 14 (01) : 103 - 112
  • [36] Development of generalized myasthenia gravis in patients with ocular myasthenia gravis - In reply
    Homel, P
    Kupersmith, MJ
    ARCHIVES OF NEUROLOGY, 2003, 60 (10) : 1492 - 1493
  • [37] PROGRESSION OF OCULAR MYASTHENIA GRAVIS TO GENERALIZED MYASTHENIA GRAVIS IN THE PEDIATRIC PATIENT
    Morris, M. E.
    Carothers, B. S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2013, 61 (02) : 423 - 423
  • [38] Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis
    Mee, J
    Paine, M
    Byrne, E
    King, J
    Reardon, K
    O'Day, J
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2003, 23 (04) : 251 - 255
  • [39] Seronegative Maternal Ocular Myasthenia Gravis and Delayed Transient Neonatal Myasthenia Gravis
    Townsel, Courtney
    Keller, Rebecca
    Johnson, Kendall
    Hussain, Naveed
    Campbell, Winston A.
    AJP REPORTS, 2016, 6 (01): : E133 - E136
  • [40] OCULAR MYASTHENIA-GRAVIS - A CRITICAL-REVIEW OF CLINICAL AND PATHOPHYSIOLOGICAL ASPECTS
    SOMMER, N
    MELMS, A
    WELLER, M
    DICHGANS, J
    DOCUMENTA OPHTHALMOLOGICA, 1993, 84 (04) : 309 - 333